PCVX Fundamental Analysis - VAXCYTE INC

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to PCVX. PCVX was compared to 536 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PCVX as it has an excellent financial health rating, but there are worries on the profitability. PCVX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

PCVX had negative earnings in the past year.

PCVX had a negative operating cash flow in the past year.

In the past 5 years PCVX always reported negative net income.

In the past 5 years PCVX always reported negative operating cash flow.

1.2 Ratios

PCVX's Return On Assets of -16.56% is fine compared to the rest of the industry. PCVX outperforms 79.85% of its industry peers.

The Return On Equity of PCVX (-17.83%) is better than 86.19% of its industry peers.

		Industry Rank	Sector Rank
ROA	-16.56%
ROE	-17.83%
ROIC	N/A

ROA(3y)-21.33%

ROA(5y)-23.51%

ROE(3y)-23.3%

ROE(5y)-26.19%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PCVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PCVX has more shares outstanding than it did 1 year ago.

The number of shares outstanding for PCVX has been increased compared to 5 years ago.

PCVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

PCVX has an Altman-Z score of 13.34. This indicates that PCVX is financially healthy and has little risk of bankruptcy at the moment.

PCVX's Altman-Z score of 13.34 is amongst the best of the industry. PCVX outperforms 87.13% of its industry peers.

There is no outstanding debt for PCVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	13.34

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 11.11 indicates that PCVX has no problem at all paying its short term obligations.

PCVX's Current ratio of 11.11 is amongst the best of the industry. PCVX outperforms 83.58% of its industry peers.

A Quick Ratio of 11.11 indicates that PCVX has no problem at all paying its short term obligations.

With an excellent Quick ratio value of 11.11, PCVX belongs to the best of the industry, outperforming 83.58% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	11.11
Quick Ratio	11.11

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.31% over the past year.

EPS 1Y (TTM)12.31%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-10.91%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.15% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-36.41%

EPS Next 2Y-25.34%

EPS Next 3Y-18.83%

EPS Next 5Y8.15%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PCVX. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PCVX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as PCVX's earnings are expected to decrease with -18.83% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-25.34%

EPS Next 3Y-18.83%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

PCVX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

VAXCYTE INC

NASDAQ:PCVX (10/3/2025, 8:00:00 PM)

After market: 43.45 +0.79 (+1.85%)

42.66

+2.53 (+6.3%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-06 2025-08-06/amc

Earnings (Next)11-03 2025-11-03

Inst Owners113.56%

Inst Owner Change0%

Ins Owners0.67%

Ins Owner Change0%

Market Cap5.54B

Analysts85.88

Price Target101.24 (137.32%)

Short Float %8.84%

Short Ratio7.35

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)0.32%

Min EPS beat(2)-2.1%

Max EPS beat(2)2.74%

EPS beat(4)3

Avg EPS beat(4)10.46%

Min EPS beat(4)-2.1%

Max EPS beat(4)28.3%

EPS beat(8)4

Avg EPS beat(8)-1.49%

EPS beat(12)6

Avg EPS beat(12)-0.3%

EPS beat(16)8

Avg EPS beat(16)-0.72%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-13.6%

PT rev (3m)-21.07%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-6.51%

EPS NY rev (1m)-3.84%

EPS NY rev (3m)-6.98%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.8
P/tB	1.8
EV/EBITDA	N/A

EPS(TTM)-4.1

EYN/A

EPS(NY)-5.96

Fwd EYN/A

FCF(TTM)-4.34

FCFYN/A

OCF(TTM)-3.54

OCFYN/A

SpS0

BVpS23.66

TBVpS23.66

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-16.56%
ROE	-17.83%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-21.33%

ROA(5y)-23.51%

ROE(3y)-23.3%

ROE(5y)-26.19%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	997.95%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	11.11
Quick Ratio	11.11
Altman-Z	13.34

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)1359.67%

Cap/Depr(5y)905.15%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)12.31%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-10.91%

EPS Next Y-36.41%

EPS Next 2Y-25.34%

EPS Next 3Y-18.83%

EPS Next 5Y8.15%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-41.34%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-38.24%

EBIT Next 3Y-17.11%

EBIT Next 5YN/A

FCF growth 1Y-156.64%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-114.32%

OCF growth 3YN/A

OCF growth 5YN/A

VAXCYTE INC (PCVX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens